Literature DB >> 11212281

Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.

S Zhou1, A Starkov, M K Froberg, R L Leino, K B Wallace.   

Abstract

Interference with mitochondrial calcium regulation is proposed to be a primary causative event in the mechanism of doxorubicin-induced cardiotoxicity. We previously reported disruption of mitochondrial calcium homeostasis after chronic doxorubicin administration (Solen et al. Toxicol. Appl. Pharmacol, 129: 214-222, 1994). The present study was designed to characterize the dose-dependent and cumulative interference with mitochondrial calcium regulation and to assess the reversibility of this functional lesion. Sprague Dawley rats were treated with 2 mg/kg/week doxorubicin s.c. for 4-8 weeks. With succinate as substrate, cardiac mitochondria isolated from rats after 4 weeks of treatment with doxorubicin expressed a lower calcium loading capacity compared with control. This suppression of calcium loading capacity increased with successive doses to 8 weeks of treatment (P < 0.05) and persisted for 5 weeks after the last doxorubicin injection, and was corroborated by dose-dependent and irreversible histopathological changes. Preincubation of mitochondria with tamoxifen, DTT, or monobromobimane did not reverse the diminished calcium loading capacity caused by doxorubicin. In contrast, incubation with cyclosporin A abolished any discernible difference in mitochondrial calcium loading capacity between doxorubicin-treated and saline-treated rats. The decrease in cardiac mitochondrial calcium loading capacity was not attributable to bioenergetic changes in the electron transport chain, because the mitochondrial coupling efficiency was not altered by doxorubicin treatment. However, the ADP/ATP translocase content was significantly lower in mitochondria from rats that received 8 weeks of doxorubicin treatment. These data indicate that doxorubicin treatment in vivo causes a dose-dependent and irreversible decrease in mitochondrial calcium loading capacity. Suppression of adenine nucleotide translocase content may be a key factor altering the calcium-dependent regulation of the mitochondrial permeability transition pore, which may account for the cumulative and irreversible loss of myocardial function in patients receiving doxorubicin chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212281

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Subcellular basis of vitamin C protection against doxorubicin-induced changes in rat cardiomyocytes.

Authors:  Ana Ludke; Anita K Sharma; Ashim K Bagchi; Pawan K Singal
Journal:  Mol Cell Biochem       Date:  2011-09-22       Impact factor: 3.396

2.  Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function.

Authors:  Asimina Hiona; Andrew Stephen Lee; Jayan Nagendran; Xiaoyan Xie; Andrew J Connolly; Robert C Robbins; Joseph C Wu
Journal:  J Thorac Cardiovasc Surg       Date:  2010-11-20       Impact factor: 5.209

Review 3.  Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging.

Authors:  Gurusher Singh Panjrath; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

4.  β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways.

Authors:  Giovanni Fajardo; Mingming Zhao; Gerald Berry; Lee-Jun Wong; Daria Mochly-Rosen; Daniel Bernstein
Journal:  J Mol Cell Cardiol       Date:  2011-07-02       Impact factor: 5.000

5.  Enhanced oxidative capacity of ground squirrel brain mitochondria during hibernation.

Authors:  Mallory A Ballinger; Christine Schwartz; Matthew T Andrews
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-01-11       Impact factor: 3.619

6.  Apoptosis in Anthracycline Cardiomyopathy.

Authors:  Jianjian Shi; Eltyeb Abdelwahid; Lei Wei
Journal:  Curr Pediatr Rev       Date:  2011-11

7.  Mrp1 localization and function in cardiac mitochondria after doxorubicin.

Authors:  Paiboon Jungsuwadee; Ramaneeya Nithipongvanitch; Yumin Chen; Terry D Oberley; D Allan Butterfield; Daret K St Clair; Mary Vore
Journal:  Mol Pharmacol       Date:  2009-02-20       Impact factor: 4.436

8.  P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.

Authors:  Wuqiang Zhu; Wenjun Zhang; Weinian Shou; Loren J Field
Journal:  Cardiovasc Res       Date:  2014-05-08       Impact factor: 10.787

9.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

10.  Adenine nucleotide translocase is involved in a mitochondrial coupling defect in MFN2-related Charcot-Marie-Tooth type 2A disease.

Authors:  Virginie Guillet; Naïg Gueguen; Christophe Verny; Marc Ferre; Chadi Homedan; Dominique Loiseau; Vincent Procaccio; Patrizia Amati-Bonneau; Dominique Bonneau; Pascal Reynier; Arnaud Chevrollier
Journal:  Neurogenetics       Date:  2009-07-18       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.